



Investment  
Banking

Canaccord Genuity

# Canaccord Genuity Digital & Tech-Enabled Health Snapshot

Q1'24 Update



# Table of Contents

A. Canaccord Genuity Digital & Tech-Enabled Health Credentials

B. Digital & Tech-Enabled Health Market Update

Appendix: Select Q1'24<sup>1</sup> Transactions

Appendix: Contact Us

---

1. 1/1/24 – 3/31/24 – “Q1'24”



Investment  
Banking

Canaccord Genuity


# Canaccord Genuity Digital & Tech-Enabled Health Credentials

Section A



# Canaccord Genuity is a Premier Investment Bank for Growth Companies

## Global and Integrated Full-Service Platform



## Deep Digital & Tech-Enabled Health Expertise

 Behavioral Health	 Benefits Management	 Care Coordination & Navigation	 Chronic Disease Management	 Clinical Software
 Data & Insights	 Employer-Sponsored Health	 Next-Gen Primary Care	 Patient Financial Engagement	 Pharma Commercialization
 Physician Enablement	 Provider Marketing	 Revenue Cycle Technology	 Telemedicine & Virtual Care	 Workforce Management

## Canaccord Genuity Overview

### Investment Banking

- 280+ investment bankers globally
- Led or participated in 359 transactions, raising over \$17.5 billion in FY 2023
- Solely focused on growth stories
- Listing capabilities on 10 stock exchanges worldwide

### Equity Research

- 115+ research professionals
- Broad industry coverage across core sectors
- 860+ companies covered
- Quest® – online valuation tool with 95% global coverage

### Sales and Trading

- Equities and fixed income
- 155+ sales and trading professionals
- 15+ fixed income professionals
- 3,000+ institutions covered
- Market making
  - 2,500+ companies

Note: All figures in CAD unless otherwise noted  
Note: Fiscal year ending 3/31/23


# Leading Mid-Market Digital & Tech-Enabled Health M&A Advisor

Dedicated M&A team with deep transaction experience across sectors and geographies

## Digital & Tech-Enabled Health Sell-Side Advisory<sup>1</sup>

Rank	Firm Name	# of Transactions 2018 – Mar'24
1	TripleTree	67
2	<b>Canaccord Genuity</b>	<b>64</b>
3	William Blair	56
4	Ziegler	38
5	Houlihan Lokey	32
6	Brentwood Capital	24
7	Raymond James	23
7	Piper Sandler	23
9	Healthcare Growth Partners	20
10	Baird	19
11	Lincoln International	18
11	Bailey & Company	18
13	Cain Brothers	17
14	Harris Williams	16
15	Evercore	14

## Select Healthcare Transactions

 Financial Advisor on sale to  Pending	 Financial Advisor on sale of its operating assets to  February 2024	 Financial Advisor on sale to  November 2023	 Financial Advisor on acquisition of  November 2023	 Financial Advisor on acquisition of  November 2023	 Financial Advisor on sale to  October 2023
 Financial Advisor on sale to  October 2023	 Financial Advisor on merger with  August 2023	 Financial Co-advisor on sale to  August 2023	 Financial Advisor on acquisition of certain assets & IP from  August 2023	 Financial Advisor on sale of its Healthcare Vertical Business to  July 2023	 Financial Advisor on investment in  May 2023
 Financial Advisor on sale to  March 2023	 Financial Advisor on sale to  March 2023	 Financial Advisor on sale to  February 2023	 Financial Advisor on growth recapitalization by  January 2023	 Financial Advisor on sale to  December 2022	 Financial Advisor on investment in  December 2022
 Financial Advisor on strategic investment from  November 2022	 Financial Advisor on sale to  October 2022	 Financial Advisor on strategic investment from  August 2022	 Financial Advisor on sale to  August 2022	 Financial Advisor on sale to  July 2022	 Financial Advisor on significant investment from  July 2022
 Financial Advisor on sale to  June 2022	 Financial Advisor on sale to  June 2022	 Financial Advisor on investment from  February 2022	 Financial Advisor on sale to  February 2022	 Financial Advisor on acquisition of  December 2021	 Financial Advisor on significant investment from  November 2021

1. Source: Canaccord Genuity database

# Leading Global Underwriter Since 2022

CG finished March 2024 as the leading global underwriter and a top global bookrunner since 2022

- Leveraging our global capabilities, CG ranks as the leading global underwriter and one of the top global bookrunners since 2022
- Underwriter on 721 total financings; Bookrunner on 573
- Transactions across US, Canada, Australia, & UK platforms

## Select CG Financings



up to \$149,367,000  
Private Placement  
Placement Agent  
March 2024



C\$28,780,000  
Follow-on Offering  
Joint Bookrunner  
March 2024



A\$38,690,000  
Follow-on Offering  
Joint Bookrunner  
March 2024



C\$75,000,000  
Follow-on Offering  
Sole Bookrunner  
February 2024



A\$325,000,000  
ASX IPO  
Joint Bookrunner  
February 2024



\$22,900,000  
Follow-on Offering  
Lead Bookrunner  
February 2024



C\$144,720,000  
Follow-on Offering  
Sole Bookrunner  
January 2024



€22,240,000  
Follow-on Offering  
Sole Bookrunner  
January 2024



A\$40,000,000  
Follow-on Offering  
Sole Bookrunner  
January 2024



\$152,700,000  
Follow-on Offering  
Co-Manager  
December 2023



€8,520,000  
Follow-on Offering  
Joint Bookrunner  
December 2023



A\$205,000,000  
Follow-on Offering  
Joint Bookrunner  
December 2023

## Global League Table (US-Focused Banks)

Global Rank <sup>1</sup>	Bank	Total Deals	Bookrun Deals	Total Proceeds (\$M)
1	Canaccord Genuity	721	573	28,515.8
2	JPMorgan	662	646	340,700.8
3	Goldman Sachs	623	604	361,847.8
4	Morgan Stanley	583	562	311,199.0
5	BofA Securities	580	553	339,952.8
6	Citi	469	454	291,243.8
7	UBS	399	385	168,963.8
8	Jefferies	345	343	106,900.2
10	Barclays	314	299	171,137.8
11	Stifel	300	196	69,862.6
13	HC Wainwright	284	213	12,581.2
14	RBC Capital Markets	281	221	110,552.3
15	Raymond James	255	121	42,122.9
16	BMO Capital Markets	252	158	74,064.7
22	Maxim Group	182	160	5,137.3
26	Wells Fargo	172	153	102,090.2
29	Deutsche Bank	161	148	116,587.1
33	AGP/Alliance Global Partners	145	136	3,153.6
34	Piper Sandler	144	118	36,609.9
35	Leerink Partners	143	138	32,437.1
43	Cantor Fitzgerald	123	97	17,425.2
45	Truist Financial	121	103	54,019.3
48	Roth Capital Partners	113	71	11,188.7
49	Evercore	110	109	45,702.7
53	EF Hutton	100	96	3,551.5
56	Guggenheim Partners	96	89	30,293.6

Source: Dealogic as of 3/31/24

1. Numbers may not be in consecutive order given the league table presented only depicts U.S. focused banks




Investment  
Banking

Canaccord Genuity

# Digital & Tech-Enabled Health Market Update

Section B



# Share Performance and Valuation Summary

## LTM<sup>1</sup> Stock Price Performance



## Summary Statistics<sup>1</sup>

	Share Performance		EV / 2024E	
	LTM	YTD	Revenue	EBITDA
NASDAQ	34.4%	10.9%	N / A	N / A
S&P 500	27.4%	10.8%	N / A	N / A
Pharma	19.1%	11.4%	6.9x	22.7x
Employer	2.1%	3.6%	2.2x	10.0x
Virtual Care and Digital Health	(11.1%)	(2.2%)	2.1x	15.4x
Provider	(19.5%)	0.8%	2.9x	12.0x
Payor	(24.3%)	(18.7%)	1.7x	9.6x
Next-Gen Primary Care	(54.5%)	(30.0%)	0.9x	19.7x

Past performance is not a guarantee of future results. Index returns are unmanaged and do not include the deduction of fees or other expenses.

## Commentary

- Following a decline in the M&A market from 2021 to 2023 of approximately 50%, Q1'24 saw an improvement in deal activity with global M&A activity of \$822 billion, representing a 39% increase compared to Q1'23
- There was a total of 17 IPOs across all industries during the first quarter of 2024 that raised a total of \$7.0B in proceeds, marking the most active Q1 since 2021 as investor confidence and appetite for new investment opportunities continues to improve
- Q1'24 marked the second consecutive quarter without an increase in the interest rate since Q3'23 as the Federal Reserve held rates steady at both of their meetings during the first quarter of the year
- The Digital and Tech-Enabled Health market performance continues to lag behind the NASDAQ and S&P 500; however, the Pharma sub-sector continues to be a bright spot driven by strong demand for solutions that improve regulatory compliance and offer data analytics and insights with a particular focus on enhancing provider and patient engagement

Source: S&P Capital IQ and Dealogic as of 3/31/24;  
Projections based off consensus analyst estimates


1. Last twelve months – "LTM"; Year to date – "YTD"; Earnings before interest, taxes, depreciation and amortization – "EBITDA"; Enterprise Value – "EV"; Estimate – "E"

• The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – "Nasdaq"  
• Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – "S&P 500"  
• Peer Group indices are based on constituents listed on slides 9 - 14 and performance is market cap weighted. Refer to the definitions on the following slides

**Driven by your success.**

# Pharma Overview

## Public Peer Group Performance



## Select Recent Transactions

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Type	Value (M) <sup>2</sup>	Target Description
Feb-24	GlocalMind	Apollo Intelligence	M&A	N/D	Offers technology-driven healthcare market research services that helps connect providers, patients and payors through data access
Feb-24	FORCE Communications	Petauri	M&A	N/D	Provides pharma clients with customized medical communication and engagement solutions through enhanced insights
Feb-24	Avant Healthcare	Real Chemistry	M&A	N/D	Offers medical communications using data-driven strategies and innovative digital and creative capabilities to facilitate impactful messaging to healthcare providers
Jan-24	Science 37	eMed	M&A	\$38	Provides a technology platform to accelerate clinical research by enabling universal clinical trial access for patients
Jan-24	Compile	McKesson	M&A	N/D	Offers a platform that captures and organizes data on healthcare professionals, facilities and patient lives and transforms into clean datasets

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 3/31/24;

Projections based off consensus analyst estimates

1. Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements; Capital Raise Value based on amount invested; \$USD in millions – “M”; Not disclosed values – “N/D”


• The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – “Nasdaq”

• Standard and Poor’s 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – “S&P 500”

• A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted

# Employer Overview

## Public Peer Group Performance



## Select Recent Transactions

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Type	Value (M) <sup>2</sup>	Target Description
Mar-24	Tava Health	Catalyst Investors	Series B	\$20	Partners with employers to offer virtual, evidence-based mental health care to bridge the gap between providers and employees
Mar-24	Healthee	Group 11 and Fin Capital	Series A	\$32	Provides a platform that answers employees' questions regarding benefits, coverage and treatment, as well as open enrollment support
Feb-24	BHS	ReviveHealth	M&A	N/D	Offers care coordination with high-touch mental health and well-being solutions to employers and higher educational institutions
Feb-24	Twill	DarioHealth	M&A	\$36	Offers a patient-led and technology-enabled platform to simplify care delivery and support healthier behaviors for improved patient outcomes
Feb-24	9amHealth	Cigna Group Ventures	Series A	\$10	Offers virtual cardiometabolic care to prevent and treat chronic conditions such as diabetes, obesity, high cholesterol and hypertension

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 3/31/24;

Projections based off consensus analyst estimates


1. Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements; Capital Raise Value based on amount invested

- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – "Nasdaq"
- Standard and Poor's 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – "S&P 500"
- A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted

# Virtual Care and Digital Health Overview

## Public Peer Group Performance



## Select Recent Transactions

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Type	Value (M) <sup>2</sup>	Target Description
Mar-24	TAO Connect	UpLift	M&A	N/D	Provides online mental health treatment intended to deliver effective therapy through higher education counseling centers and employee assistance programs
Mar-24	TeleMed2U	Kayne Anderson	M&A	N/D	Offers telemedicine solutions and end to end patient services to provide quality affordable care within various specialty care segments
Jan-24	Forta Health	Insight Partners	Series A	\$55	Provides an applied behavior analysis therapy platform empowering parents to assist their children in learning and development through personalized care plans
Jan-24	Doc.com	Silver Rock	Capital Raise	\$300	Offers a decentralized telehealth platform providing free basic healthcare and health education globally
Jan-24	Vita Health	CVS Health Ventures and LFE Capital	Series A	\$23	Offers telehealth specialized in suicide care as well as teletherapy and psychiatry services for individuals living with a broad spectrum of behavioral health conditions

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 3/31/24;

Projections based off consensus analyst estimates


1. Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements; Capital Raise Value based on amount invested

- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – “Nasdaq”
- Standard and Poor’s 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – “S&P 500”
- A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted

# Provider Overview

## Public Peer Group Performance



## Select Recent Transactions

● Indicates a Canaccord Genuity-led transaction

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Type	Value (M) <sup>2</sup>	Target Description
Mar-24	CodaMetrix	Transformation Capital	Series B	\$40	Provides AI-powered solutions for transforming healthcare and revenue cycle management through autonomous coding
Feb-24	● Healthwise	WebMD Health Corp	M&A	N/D	Provides evidence-based health education, technology and services to help patients make better health decisions
Feb-24	Abridge	Lightspeed Venture Partners	Series C	\$150	Offers an AI platform that converts a patient-clinician conversation into clinical notes and integrates information directly into electronic medical records
Feb-24	Agilio Software	Five Arrows and TA Associates	M&A	N/D	Offers frontline healthcare operations software that digitizes critical operational functions such as people management, compliance and clinical asset tracking
Feb-24	PatientFi	Questa Capital	Capital Raise	\$25	Offers medical practices a comprehensive technology suite of payment solutions to help patients pay for elective procedures

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 3/31/24;

Projections based off consensus analyst estimates


1. Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements; Capital Raise Value based on amount invested

- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – “Nasdaq”
- Standard and Poor’s 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – “S&P 500”
- A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted

# Payor Overview

## Public Peer Group Performance



## Select Recent Transactions

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Type	Value (M) <sup>2</sup>	Target Description
Mar-24	Pharmacy Quality Solutions	Innovaccer	M&A	N/D	Offers solutions that connect healthcare payers and pharmacies to standardize reporting on key medication use and improve overall population health
Mar-24	HiLabs	Denali Growth Partners and Eight Roads Ventures	Series B	\$39	Offers a cloud-based platform that aims to provide healthcare organizations with clean data to help improve patient outcomes
Feb-24	Cotiviti	KKR and Veritas	M&A	N/D	Provides advanced technology and data analytics for healthcare payers to deliver improved payment accuracy, risk adjustment and clinical analytics
Feb-24	Cohere Health	Deerfield Management Company	Series B	\$50	Offers clinical intelligence and prior authorization automation solutions to reduce administrative expenses and improve patient outcomes
Jan-24	ClarisHealth	Pamlico Capital	Capital Raise	N/D	Creates a better way to drive claims payment accuracy for health plans through its integrated technology platform

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 3/31/24;

Projections based off consensus analyst estimates


1. Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements; Capital Raise Value based on amount invested

• The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – “Nasdaq”  
 • Standard and Poor’s 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – “S&P 500”  
 • A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted

# Next-Gen Primary Care Overview

## Public Peer Group Performance



## Select Recent Transactions

Announced	Target	Buyer / Investor(s) <sup>1</sup>	Type	Value (M) <sup>2</sup>	Target Description
Mar-24	CardioOne	WindRose Health Investors	M&A	N/D	Provides integrated technology and administrative support for independent providers entering value-based care to enhance patient and provider experiences
Feb-24	Healthy	Corbel Capital Partners	Capital Raise	N/D	Offers solutions that prioritizes primary care, support services and preventative medicine to improve health outcomes
Feb-24	Everside Health	Marathon Health	M&A	N/D	Provides advanced primary care and occupational health to increase employee and union-member access to better care and drive improved health outcomes
Jan-24	Accompany Health	Venrock	Series A	\$56	Provides 24/7 in-home and virtual care services, including primary care and urgent care for low-income patients
Jan-24	Summa Health	HATCo	M&A	N/D	Offers an integrated healthcare delivery system encompassing a network of hospitals, community medical centers, health plans, accountable care organizations and multi-specialty physician organizations

Sources: S&P Capital IQ, MergerMarket and Pitchbook as of 3/31/24;

Projections based off consensus analyst estimates

1. Selected investors

2. M&A Transaction Value represents Enterprise Value at announcements; Capital Raise Value based on amount invested

- The Nasdaq Composite Index is a market-capitalization-weighted index of all the stocks traded on the Nasdaq stock exchange and includes companies based outside the United States – “Nasdaq”
- Standard and Poor’s 500 Index is a capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries – “S&P 500”
- A Peer Group index is one that groups individual companies together into a single, benchmark index. This refers to the list of select peers to the left of the chart. Performance is market cap-weighted



**Investment  
Banking**

Canaccord Genuity

# Select Q1'24 Transactions

Appendix



# Select Q1'24 M&A Transactions

Ann. Date	Target	Acquiror	Sub-sector	Enterprise Value (\$M)	EV /	
					LTM Rev.	LTMEBITDA
Mar-24	KMK Optometry	Axcel Learning	Provider	N/D	N/D	N/D
Mar-24	Health+Commerce	Supreme Group	Pharma	N/D	N/D	N/D
Mar-24	BirchAI	Sagility	Payor	N/D	N/D	N/D
Mar-24	Alight, Select Business Units <sup>1</sup>	H.I.G. Capital	Employer	\$1,200	N/D	10.0x
Mar-24	Actium Health	Syllable AI	Provider	N/D	N/D	N/D
Mar-24	Manta Health Tech	Anatomy IT	Provider	N/D	N/D	N/D
Mar-24	RevSpring	Frazier Healthcare	Provider	\$1,300	N/D	13.0x
Mar-24	Pharmacy Quality Solutions	Innovaccer	Payor	N/D	N/D	N/D
Mar-24	Fortrea, Select Business Units <sup>2</sup>	Arsenal Capital	Pharma	\$345	N/D	N/D
Mar-24	Triyam	Access Information Management	Provider	N/D	N/D	N/D
Mar-24	Aural Analytics	Linus Health	Provider	N/D	N/D	N/D
Mar-24	TeleMed2U	Kayne Anderson Growth Capital	Virtual Care and Digital Health	N/D	N/D	N/D
Mar-24	TAO Connect	UpLift	Virtual Care and Digital Health	N/D	N/D	N/D
Mar-24	HearWorks	Practis	Provider	N/D	N/D	N/D
Mar-24	Health Dialog, Select Business Units <sup>3</sup>	Carenet Health	Payor	N/D	N/D	N/D
Mar-24	Calyx	Invicro	Pharma	N/D	N/D	N/D
Mar-24	TDO Software	Valsoft Corporation	Provider	N/D	N/D	N/D
Mar-24	Kinsa Health	Healthy Together	Provider	N/D	N/D	N/D
Mar-24	Lyfebulb Holdings	Patient Care America	Virtual Care and Digital Health	N/D	N/D	N/D
Mar-24	Breitenbach	RLDatix	Provider	N/D	N/D	N/D
Mar-24	CardioOne	WindRose Health Investors	Next-Gen Primary Care	N/D	N/D	N/D
Feb-24	● Healthwise	WebMD Health	Provider	N/D	N/D	N/D
Feb-24	vcpi	DAS Health	Provider	N/D	N/D	N/D
Feb-24	BHS	ReviveHealth	Employer	N/D	N/D	N/D
Feb-24	Rebellis Group	Toney Healthcare	Payor	N/D	N/D	N/D
Feb-24	SciencelO	Veradigm	Provider	\$140	N/D	N/D
Feb-24	SourcEdge	Alivia Analytics	Payor	N/D	N/D	N/D
Feb-24	Automated Healthcare Solutions	AdvancedRx	Provider	N/D	N/D	N/D
Feb-24	MD Connect	Intellibright	Provider	N/D	N/D	N/D
Feb-24	AssistRx	WCAS	Pharma	N/D	N/D	N/D
Feb-24	Figure 1	Physician's Weekly	Provider	N/D	N/D	N/D

Source: Company filings, Mergermarket and press releases

Note: \$USD in millions

1. Includes payroll and professional services business units

2. Includes endpoint clinical and patient access businesses; EV includes an earnout

3. Includes nurse advice line, chronic care management solution and shared decision-making solution

● Indicates a Canaccord Genuity-led transaction

## Select Q1'24 M&A Transactions (cont.)

Ann. Date	Target	Acquiror	Sub-sector	Enterprise Value (\$M)	EV /	
					LTM Rev.	LTMEBITDA
Feb-24	PeopleKeep	Remodel Health	Employer	N/D	N/D	N/D
Feb-24	Virtual Health Holdings	WPF Holdings	Virtual Care and Digital Health	N/D	N/D	N/D
Feb-24	Healint	Aptar Digital Health	Pharma	N/D	N/D	N/D
Feb-24	Twill	DarioHealth	Employer	\$36	1.9x	N/D
Feb-24	GlocalMind	Apollo Intelligence	Pharma	N/D	N/D	N/D
Feb-24	Agilio	Five Arrows and TA Associates	Provider	N/D	N/D	N/D
Feb-24	Vimly Benefit Solutions	Rubicon Technology Partners	Payor	N/D	N/D	N/D
Feb-24	MedVR Education	NBME	Provider	N/D	N/D	N/D
Feb-24	Visante	Avesi Partners	Provider	N/D	N/D	N/D
Feb-24	Danam Health	Assure Holdings	Pharma	N/D	N/D	N/D
Feb-24	Kolter Solutions	Tandym	Employer	N/D	N/D	N/D
Feb-24	Cotiviti	KKR and Veritas	Payor	N/D	N/D	N/D
Feb-24	AmeriPro Health	Whistler Capital Partners	Provider	N/D	N/D	N/D
Feb-24	Inception Point Systems	Symplr Software	Payor	\$247	5.6x	N/D
Feb-24	CPS	Undisclosed Buyer	Provider	N/D	N/D	N/D
Feb-24	Everside Health	Marathon Health	Next-Gen Primary Care	N/D	N/D	N/D
Feb-24	FORCE Communications	Petauri	Pharma	N/D	N/D	N/D
Feb-24	SILAS	CentralReach	Provider	N/D	N/D	N/D
Feb-24	Continuum Clinical	Spectrum Science	Pharma	N/D	N/D	N/D
Feb-24	KidneySoft	MealPro	Virtual Care and Digital Health	N/D	N/D	N/D
Feb-24	Avant Healthcare	Real Chemistry	Pharma	N/D	N/D	N/D
Feb-24	HealthScape Advisors	Chartis	Payor	N/D	N/D	N/D
Feb-24	Delegated DDS	Fluent	Provider	N/D	N/D	N/D
Feb-24	VigiLanz	Inovalon	Provider	N/D	N/D	N/D
Feb-24	Health Prime	Aquiline Capital Partners	Provider	N/D	N/D	N/D
Feb-24	Pharma Logistics	Assured Healthcare Partners	Pharma	N/D	N/D	N/D
Feb-24	ResolutionMD	Bayan Software	Provider	N/D	N/D	N/D
Jan-24	Specialty Networks	Cardinal Health	Provider	\$1,200	N/D	N/D
Jan-24	Gyant	Fabric	Provider	N/D	N/D	N/D
Jan-24	Science 37	eMed	Pharma	\$38	0.6x	NMF
Jan-24	Workshop Wizard	Constellation Quality Health	Provider	N/D	N/D	N/D

Source: Company filings and press releases  
Note: \$USD in millions

## Select Q1'24 M&A Transactions (cont.)

Ann. Date	Target	Acquiror	Sub-sector	Enterprise Value (\$M)	EV /	
					LTM Rev.	LTMEBITDA
Jan-24	Intrahealth	HEALWELL AI	Provider	\$24	2.0x <sup>1</sup>	N/D
Jan-24	Vitals Software	Aline	Provider	N/D	N/D	N/D
Jan-24	PacMed	Harris	Provider	N/D	N/D	N/D
Jan-24	EyecareLive	Visibly	Virtual Care and Digital Health	N/D	N/D	N/D
Jan-24	InquisitHealth	Pyx Health	Payor	N/D	N/D	N/D
Jan-24	Summa Health	HATCo	Next-Gen Primary Care	N/D	N/D	N/D
Jan-24	CPSI's American Health Tech	PointClickCare	Provider	N/D	N/D	N/D
Jan-24	Inceptua Group	Vesey Street Capital Partners	Pharma	N/D	N/D	N/D
Jan-24	ID Medical	Aya Healthcare	Provider	N/D	N/D	N/D
Jan-24	Compliance Risk Analyzer	VMG Health	Provider	N/D	N/D	N/D
Jan-24	Billing Dynamix	ClinicMind	Provider	N/D	N/D	N/D
Jan-24	Bright.MD	98point6	Provider	N/D	N/D	N/D
Jan-24	Cured	Innovaccer	Provider	N/D	N/D	N/D
Jan-24	Vivisum	ZoomRx	Pharma	N/D	N/D	N/D
Jan-24	ABG Anesthesia Data Group	Graphium Health	Provider	N/D	N/D	N/D
Jan-24	J+D Forecasting	Evaluate	Pharma	N/D	N/D	N/D
Jan-24	Medata	MedRisk	Payor	N/D	N/D	N/D
Jan-24	Verifi Dental	iCoreConnect	Provider	N/D	N/D	N/D
Jan-24	Professional Medical Services	Elevate Patient Financial Solutions	Provider	N/D	N/D	N/D
Jan-24	Fivos Medstreaming Software	Harris	Provider	N/D	N/D	N/D
Jan-24	MIM Software	GE HealthCare	Provider	N/D	N/D	N/D
Jan-24	ADVOCATE RCM	Ventra Health	Provider	N/D	N/D	N/D
Jan-24	Biscom	Concord Technologies	Provider	N/D	N/D	N/D
Jan-24	Compile	McKesson	Pharma	N/D	N/D	N/D
Jan-24	Genesis Chiropractic	ClinicMind	Provider	N/D	N/D	N/D
Jan-24	Espyr	Acentra Health	Employer	N/D	N/D	N/D
Jan-24	Drug Channels Institute	HMP Global	Pharma	N/D	N/D	N/D
Jan-24	MoonlightOrtho	HOPCo	Virtual Care and Digital Health	N/D	N/D	N/D
Jan-24	Teamworx Dental	iCoreConnect	Provider	N/D	N/D	N/D
Jan-24	Santa Barbara Actuaries	Arbital Health	Payor	N/D	N/D	N/D
Jan-24	Koha Health	Veradigm	Provider	N/D	N/D	N/D

Source: Company filings and press releases

Note: \$USD in millions

1. Multiple based on 2024E Revenue



Canaccord Genuity

# Contact Us

Appendix



# Canaccord Genuity Team Contacts

## Global Full-Service Team

### US TEAM

#### Tom O'Connor

Managing Director & Co-Head US  
Healthcare Investment Banking

*New York*

[toconnor@cgf.com](mailto:toconnor@cgf.com)

#### Matthew Kebel

Managing Director

*New York*

[mkebel@cgf.com](mailto:mkebel@cgf.com)

#### Steven Quinn

Managing Director

*New York*

[squinn@cgf.com](mailto:squinn@cgf.com)

#### Fred Fang

Director

*Nashville*

[ffang@cgf.com](mailto:ffang@cgf.com)

#### Henry Hamlin

Vice President

*Nashville*

[hhamlin@cgf.com](mailto:hhamlin@cgf.com)

#### Rob Higham

Vice President

*Boston*

[rhigham@cgf.com](mailto:rhigham@cgf.com)

### EUROPEAN TEAM

#### Julie Langley

Head of Technology &  
Healthcare Advisory, Europe

*London*

[jlangley@cgf.com](mailto:jlangley@cgf.com)

#### Kevin Bottomley

Managing Director

*London*

[kbottomley@cgf.com](mailto:kbottomley@cgf.com)

#### Kunal Kadiwar

Managing Director

*London*

[kkadiwar@cgf.com](mailto:kkadiwar@cgf.com)

#### David Sanders

Managing Director

*London*

[dsanders@cgf.com](mailto:dsanders@cgf.com)

# Disclosures

This material is provided for information purposes only and is intended for distribution in those jurisdictions where subsidiaries of Canaccord Genuity Group Inc. (together, "Canaccord Genuity") are registered as advisors or dealers in securities. Any distribution or dissemination of this material in any other jurisdiction is strictly prohibited. The information does not constitute an offer or solicitation in any jurisdiction in which such an offer or solicitation is not authorized, or to any person to whom it is unlawful to make such an offer or solicitation. This is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs to any person. Clients should obtain advice based on their own individual circumstances before making an investment decision. Any client wishing to effect any transactions should do so through a Canaccord Genuity qualified salesperson in their jurisdiction of residence.

The information contained herein has been compiled by Canaccord Genuity from sources believed to be reliable, but no representation or warranty, express or implied, is made by Canaccord Genuity or any other person to its fairness, accuracy, completeness or correctness. To the fullest extent permitted by law, neither Canaccord Genuity nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained herein.

All material presented in this document, unless specifically indicated otherwise, is under trademark and copyright to Canaccord Genuity. None of the material, or its content, or any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of Canaccord Genuity.

Note to Readers: This report was created by members of the investment banking department of Canaccord Genuity LLC ("Canaccord" or "Canaccord Genuity") and has not been reviewed by or discussed with any members of the Canaccord Genuity research department. This report is not intended to be, and in no way constitutes, a "research report," as such term is defined by Rule 137 promulgated under the Securities Act of 1933, as amended. Canaccord Genuity's investment banking department has done, and may continue to do, business with companies included in this report. This document is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. This report is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to corporate and institutional clients and does not have regard for the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, neither Canaccord Genuity, its affiliates nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained in this report. Past performance is not indicative of future results. Canaccord Genuity LLC is a registered broker-dealer regulated by the SEC and FINRA. Member SIPC. Offices in other countries are offices of other companies in the Canaccord group of companies. See <https://www.canaccordgenuity.com/investor-relations/investor-resources/contact-us/our-companies/> for more information.

Copyright © Canaccord Genuity Corp. 2024. – Member CIRO/Canadian Investor Protection Fund

Copyright © Canaccord Genuity Limited 2024. – Member of the London Stock Exchange, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2024. – Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited 2024. – Authorized and regulated by ASIC.

## CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This document may contain certain "forward-looking information" (as defined under applicable securities laws). These statements relate to future events or future performance and include management's expectations, beliefs, plans, estimates, intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts, business and economic conditions and Canaccord Genuity Group LLC's (the "Company") growth, results of operations, market position, ability to compete and future financial or operating performance of the Company, performance and business prospects and opportunities. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue", "target", "intend", "could" or the negative of these terms or other comparable terminology. By its very nature, forward-looking information involves inherent risks and uncertainties, both general and specific, and a number of factors could cause actual events or results to differ materially from the results discussed in the forward-looking information. In evaluating these statements, readers should specifically consider various factors, which may cause actual results to differ materially from any forward-looking statement. These factors include, but are not limited to, market and general economic conditions, the nature of the financial services industry, the risks and uncertainties discussed from time to time in the Company's interim and annual consolidated financial statements and its Annual Information Form filed on [www.sedar.com](http://www.sedar.com). Readers are cautioned that the preceding list of material factors or assumptions is not exhaustive. Except as may be required by applicable law, the Company does not undertake, and specifically disclaims, any obligation to update or revise any forward-looking information, whether as a result of new information, future developments or otherwise.